Patents by Inventor Benoit van den Eynde

Benoit van den Eynde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof
    Patent number: 6025474
    Abstract: The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-3. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Uses of these materials in therapeutic and diagnostic contexts are also a part of the invention.
    Type: Grant
    Filed: November 12, 1997
    Date of Patent: February 15, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Benoit Van den Eynde, Pierre van den Bruggen, Thierry Boon-Falleur
  • Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
    Patent number: 6013481
    Abstract: A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as GAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described. Tumor rejection antigens are also shown.
    Type: Grant
    Filed: June 24, 1996
    Date of Patent: January 11, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Olivier DeBacker, Benoit van den Eynde, Thierry Boon-Falleur
  • Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof
    Patent number: 5939526
    Abstract: The invention describes the RAGE tumor rejection antigen precursor family, including nucleic acids encoding such tumor rejection antigen precursors, tumor rejection antigen peptides or precursors thereof and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a RAGE tumor rejection antigen precursor.
    Type: Grant
    Filed: September 20, 1995
    Date of Patent: August 17, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Beatrice Gaugler, Benoit Van den Eynde, Peter Schrier, Nathalie Brouwenstijn, Thierry Boon-Falleur
  • Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
    Patent number: 5925729
    Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
    Type: Grant
    Filed: May 2, 1994
    Date of Patent: July 20, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre Van Der Bruggen, Benoit Van Den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari
  • Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
    Patent number: 5858689
    Abstract: A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as GAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described. Tumor rejection antigens are also shown.
    Type: Grant
    Filed: September 21, 1995
    Date of Patent: January 12, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre van der Bruggen, Benoit van den Eynde, Olivier DeBacker, Thierry Boon-Falleur
  • Isolated cytolytic T cells specific for complexes of MAGE related peptides and HLA molecules
    Patent number: 5695994
    Abstract: The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by HLA molecules HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: December 9, 1997
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurguin, Catia Traversari, Beatrice Gaugler, Benoit Van den Eynde
  • Isolated peptides derived from tumor rejection antigens, and their use
    Patent number: 5648226
    Abstract: A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as GAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described. Tumor rejection antigens are also shown.
    Type: Grant
    Filed: January 10, 1995
    Date of Patent: July 15, 1997
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Benoit Van den Eynde, Olivier DeBacker, Thierry Boon-Falleur
  • Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
    Patent number: 5610013
    Abstract: A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as GAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described.
    Type: Grant
    Filed: May 27, 1994
    Date of Patent: March 11, 1997
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Benoit Van den Eynde, Thierry Boon-Falleur
  • Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3
    Patent number: 5512437
    Abstract: A method for determining head and neck squamous cell carcinomas, bladder tumors and prostate carcinomas is described. The method involves assaying for expression of the gene coding for tumor rejection antigen precursor MAGE-3, or its expression product. Various assays, and kits useful for these assays, are described.
    Type: Grant
    Filed: March 1, 1994
    Date of Patent: April 30, 1996
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Beatrice Gaugler, Thierry Boon-Falleur, Benoit van den Eynde, Etienne DePlaen, Francis Basseur, Bernard Lethe, Pierre van der Bruggen
  • Isolated nucleic acid molecules which encode MAGE derived nonapeptides
    Patent number: 5462871
    Abstract: The invention relates to isolated nucleic acid molecules which encode nonapeptides derived from MAGE tumor rejection antigen precursors. The nonapeptides form complexes with human leukocyte antigens presented on the surfaces of cells, and lead to lysis of these cells by cytolytic T lymphocytes. Thus, they are useful in diagnostic methods. Also a part of the invention are vectors which are designed to encode the nonapeptides as well as cell lines which have been transformed or transfected with the isolated nucleic acid molecules of the invention, or vectors including these molecules.
    Type: Grant
    Filed: June 7, 1993
    Date of Patent: October 31, 1995
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurquin, Catia Traversari, Beatrice Gaugler, Benoit Van den Eynde
  • Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
    Patent number: 5342774
    Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
    Type: Grant
    Filed: December 12, 1991
    Date of Patent: August 30, 1994
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre van der Bruggen, Benoit Van den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari